Perrigo Company Current Deferred Revenue Over Time
| PRGO Stock | USD 28.84 0.50 1.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Perrigo Company Performance and Perrigo Company Correlation. Perrigo |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Perrigo Company. If investors know Perrigo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Perrigo Company listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Dividend Share 1.101 | Earnings Share (1.07) | Revenue Per Share 32.088 | Quarterly Revenue Growth (0.03) |
The market value of Perrigo Company is measured differently than its book value, which is the value of Perrigo that is recorded on the company's balance sheet. Investors also form their own opinion of Perrigo Company's value that differs from its market value or its book value, called intrinsic value, which is Perrigo Company's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Perrigo Company's market value can be influenced by many factors that don't directly affect Perrigo Company's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Perrigo Company's value and its price as these two are different measures arrived at by different means. Investors typically determine if Perrigo Company is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Perrigo Company's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Perrigo Company and related stocks such as Prestige Brand Holdings, Amphastar P, and Deciphera Pharmaceuticals Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PBH | (2 M) | 836 K | 836 K | 836 K | 836 K | 836 K | 492 K | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 3 M | 1.9 M |
| AMPH | 642 K | 642 K | 642 K | 643 K | 14 M | 643 K | 97 K | (56.1 M) | (56.1 M) | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.4 M | 1.5 M |
| PCRX | 2 M | 13.1 M | 972 K | 1 M | 1.4 M | 1.4 M | 595 K | 102 K | 71.8 M | 71.8 M | 71.1 M | 10.1 M | 34 M | 39.1 M | 41.1 M |
| COLL | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | 4.9 M | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (14.4 M) | (13.7 M) |
| PAHC | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 33.9 M | 33.9 M | 41.4 M | 3.6 M | 52.8 M | 44.8 M | 58.9 M | 822 K | 54.9 M | 2.9 M | 2.8 M |
| ELAN | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 116 M | 148.6 M | 185 M | 524 M | 602.6 M | 632.7 M |
| RDY | 382 M | 39 M | 553 M | 678 M | 1.1 B | 659 M | 819 M | 982 M | 1.4 B | 1.9 B | 2 B | 2.6 B | 2 B | 1.4 B | 1.4 B |
| ANIP | 136.4 K | 47 K | 47 K | 47 K | 24 M | 24 M | 24 M | 24 M | 711 K | 451 K | 80 K | 87 K | 32.5 M | 37.4 M | 39.2 M |
| KMDA | 2.8 M | 7.3 M | 8.2 M | 5.5 M | 2.8 M | 1.9 M | 4.9 M | 4.9 M | 461 K | 589 K | 2 M | 40 K | 35 K | 325 K | 308.8 K |
Perrigo Company and related stocks such as Prestige Brand Holdings, Amphastar P, and Deciphera Pharmaceuticals Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Perrigo Company PLC | PRGO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Ireland |
| Exchange | New York Stock Exchange |
USD 28.84
Check out Perrigo Company Performance and Perrigo Company Correlation. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Perrigo Company technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.